Targeting ALK: Precision Medicine

Anaplastic Lymphoma Kinase (ALK) is an oncogene frequently found as a fusions in non-small cell lung cancer (NSCLC), as EML4-ALK. Precision medicine uses therapeutic agents that target specific mutations, such as those found in ALK-positive NSCLC patients. Discover the latest research on Targeting ALK here.

June 19, 2020
Case Report
Open Access

Breast Implant-Associated Anaplastic Large Cell Lymphoma

Case Reports in Pathology
P L MooriJ Iddon
June 17, 2020

Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Linling JinXin Zhao
June 17, 2020

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Yubo WangYong He
June 17, 2020

Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Takahito MizunoFumiko Ohtsu
June 25, 2020
Case Report

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis

Respiratory Medicine Case Reports
Yutaka TakaharaShiro Mizuno
June 11, 2020

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Ruoshi ShiGeoffrey Liu
June 22, 2020

Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Jing ZhengJianying Zhou
July 1, 2020
Comment / Editorial

Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Herbert H LoongYat-Ming Lau
June 25, 2020
Open Access

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

Journal of Clinical Medicine
Ramon Andrade De MelloGeorgios Antoniou
July 3, 2020
Case Report

A case of ALK- rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone

Respiratory Medicine Case Reports
Yoshihiro MiyashitaToshio Oyama
June 25, 2020
Case Report

Nivolumab-induced contact dermatitis in a patient with advanced lung cancer

Respiratory Medicine Case Reports
Shintaro SatoHidekazu Matsushima
June 25, 2020
Case Report

Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib

Clinical Lung Cancer
Xiaofeng ChenDerong Zhang

Sign up to follow this feed and discover related papers.

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2020 Meta ULC. All rights reserved